Science 37 Holdings, Inc. (NASDAQ: SNCE – Get Rating) received a significant drop in short interest rates in May. As of May 15, there was a short interest amounting to a total of 892,100 shares, down 34.9% from a total of 1,370,000 shares on April 30. Currently, 1.1% of the company’s shares have been sold short. Based on an average trading volume of 278,300 shares, the ratio of days to coverage is currently 3.2 days.
Institutional investors have recently changed their holdings in business. Citigroup Inc. bought a new stake in Science 37 in the first quarter worth $ 37,000. Virtu Financial LLC bought a new position in shares of Science 37 in the first quarter worth about $ 60,000. increased its stake in shares of Science 37 by 29.0% in the first quarter. JPMorgan Chase & Co. now owns 14,574 shares of the company’s stock worth $ 78,000 after acquiring an additional 3,272 shares during the period. Penserra Capital Management LLC bought a new position in shares of Science 37 in the 4th quarter worth about $ 92,000. Finally, Shay Capital LLC bought a new position in shares of Science 37 in the first quarter worth about $ 120,000. 46.12% of the shares are owned by hedge funds and other institutional investors.
SNCE has been the subject of a number of research reports. Robert W. Baird confirmed the “buy” rating and issued a $ 12.00 target price for shares of Science 37 in a research note on Friday, April 8. Zacks Investment Research downgraded Science 37 from a “buy” rating to a “retention” rating in a report on Friday. One research analyst rated the shares with a retention rating, and four gave a rating to buy the company’s shares. Based on data from MarketBeat.com, the shares currently have an average Buy rating and a consensus target price of $ 12.38.
SNCE opened for $ 3.68 on Friday. The business has a 50-day moving average price of $ 4.17 and a 200-day moving average price of $ 7.67. Science 37 has a twelve-month low of $ 2.75 and a twelve-month high of $ 15.10.
Science 37 (NASDAQ: SNCE – Get Rating) last released its earnings results on Tuesday, March 22nd. The company reported ($ 0.29) earnings per share (EPS) for the quarter. The company had revenue of $ 20.38 million for the quarter, compared to analysts’ estimates of $ 15.02 million. Stock analysts expect Science 37 to report -0.45 earnings per share for the current year.
About science 37 (Get an estimate)
Science 37 Holdings, Inc. is developing a technology platform that allows for flexible clinical trials and specialized trials to organize trials. The company is developing a flexible clinical trial operating system that enables modern and digital approaches to clinical trials, bringing together all countries, including patients and researchers, nurses, coordinators, and sponsors. to power workflows, centralize evidence generation, and harmonize data.
This instant news alert is generated by narrative scientific technology and financial data from MarketBeat to provide readers with the fastest and most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Do you need to invest $ 1,000 in Science 37 right now?
Before you think about Science 37, you will want to hear this.
MarketBeat monitors the highest rated and performing Wall Street analysts and promotions they recommend to their customers on a daily basis. MarketBeat has identified five stocks that top analysts are quietly whispering to their customers to buy now, before the wider market catches on … and Science 37 was not on the list.
While Science 37 currently has a “Buy” rating among analysts, the highest rated analysts believe that these five stocks are better purchases.
See the 5 shares here